Attenuated Mengo Virus: a New Vector for Live

Abstract

Several features make Mengo virus an excellent candidate for use as a vaccine vector. The virus has a wide host range, including rodents, pigs, monkeys, and most likely humans, and expresses its genome exclusively in the cytoplasm of the infected cell. Stable attenuated strains exist which are deleted for part of the 5 * noncoding region of the genome. Here we report an attenuated Mengo virus recombinant, vLCMG4, that encodes an immunodominant cytotoxic T-lymphocyte epitope of the lymphocytic choriomeningitis virus (LCMV) nucleo-protein. vLCMG4 induced protective immunity against lethal LCMV infection after a single, low-dose immu-nization in BALB/c mice and elicited an LCMV-specific CD81 cytotoxic T lymphocyte response. This demon-strates the potential of recombinant Mengo virus vaccines to confer protection against infectious diseases by the induction of cellular immune responses. With the advent of molecular biology, the engineering of efficacious live recombinant viral vaccines has become pos-sible. These recombinant vaccines are constructed with atten-uated strains of otherwise pathogenic viruses, e.g., adeno-virus (12, 16) and poliovirus (4, 7, 11), or viruses with relatively mild pathogenicity, such as the poxviruses (17, 24), huma

Similar works

Full text

thumbnail-image
oai:CiteSeerX.psu:10.1.1.919.8631Last time updated on 11/1/2017

This paper was published in CiteSeerX.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.